Seven years on from Sutent and renal cell cancer still needs biomarkers
This article was originally published in Scrip
Renal cell carcinoma (RCC) treatment is in dire need of relevant biomarkers. With the availability of numerous treatment options in RCC, clinicians are faced with the daunting task of determining the optimal approach with barely any clues as to what will work best. And with 63 drugs in the RCC pipeline, as identified by new analysis from Datamonitor Healthcare, Pipeline: Renal Cell Cancer, the situation is only set to get more complicated.